Our proprietary novel technology platform is an advanced stem cell culture system the CELLvo™ Matrix. It replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Our unique technology enables users to isolate and grow stem cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue.
OUR CORE NOVEL TECHNOLOGY PLATFORM IS AN ADVANCED STEM CELL CULTURE SYSTEM – CELLvo™ MATRIX. THE CELLvo™ MATRIX REPLICATES THE 3-DIMENSIONAL “HOME” IN WHICH STEM CELLS NATURALLY RESIDE AND PROLIFERATE.
Stem cells grown in CELLvo™ Matrix remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells.
The CELLvo™ Matrix architecture also has enabled us to isolate and expand multi-potent stem cells from human umbilical cord blood (hUCB-SCs), a non-controversial and plentiful resource. This patent-pending process produces non-differentiated stem cells capable of producing tissues from all 3 developmental germ layers.
In pursuing proof-of-concept, we have documented how our hUCB-SCs, when implanted into experimental animals, produce discrete bundles of various human tissues, including muscle, nerve, bone, adipose and glandular tissues. StemBioSys® will explore the clinical effects of the trophic hormones, mediators and growth factors produced by and associated with these stem cells.